Search Results
Dec 10, 2025, 04:15 ET Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
NCT05104125) and Phase III (NCT06192264) studies of denifanstat (ASC40) for the treatment of moderate-to-severe acne vulgaris.In the Phase III study, denifanstat (ASC40) met
More news about: Ascletis Pharma Inc.
Dec 10, 2025, 04:12 ET Aerolase Earns Dual Honors in MedEsthetics 2025 Readers' Choice Awards
dermal layers.In a clinical study of 25 patients aged 38-61, researchers found that 86% of participants showed significant increases in Type III collagen production, with 57% demonstrating notable Type I collagen increases one-month post-treatment. Histological analysis revealed increased collagen
More news about: Aerolase
Dec 10, 2025, 02:00 ET Hello Group Inc. Announces Unaudited Financial Results for the Third Quarter of 2025
(iii) Includes tax impacts related to the amortization of intangible assets from business acquisition. There is no tax impact related to share-based compensation.
More news about: Hello Group Inc.
Dec 09, 2025, 20:30 ET D3 Bio Secures $108 Million in Series B Financing to Advance Global Clinical Programs
D3 Bio's innovative pipeline and its global development strategy.Proceeds from this financing will primarily support the planned global Phase III pivotal program for the company's lead asset, elisrasib (D3S-001). These pivotal trials will assess elisrasib as both a monotherapy and in combination
More news about: D3 Bio, Inc.
Dec 09, 2025, 20:29 ET Perkembangan Layanan Bybit untuk Investor Institusi pada 2026 Jadi Topik Pembahasan di Sebuah Acara Penting yang Berlangsung di Abu Dhabi
ini membutuhkan kepastian — baik dari sisi likuiditas, regulasi, dan kinerja. Dengan arus modal masuk yang meningkat dari USD 1,3 miliar pada Triwulan III menjadi USD 2,88 miliar pada Triwulan IV, peran kami semakin jelas: kami membangun infrastruktur paling tepercaya sebagai babak baru di sektor keuangan
More news about: Bybit
Dec 09, 2025, 19:00 ET 李氏大藥廠收購 Staccato® One Breath Technology® 平台技術及相關資產，推動產品管線擴展並深化與 UCB 的全球合作
的全球合作除上述收益外，公司還收購 Alexza 在現有全球許可及製造供應協議下的權利和義務，該協議的合作方 UCB 為在癲癇治療領域具有強大影響力的生物製藥公司。根據協議，UCB 持有並將繼續保有 Staccato® 阿普唑仑的全球開發和商業化權利，該產品目前處於 III 期臨床試驗階段（ClinicalTrial.gov ID: NCT05077904），進一步驗證了 Staccato® OBT® 技術平台的臨床成熟度和商業潛力。UCB 於 2020 年 6 月收購 Engaged Therapeutics, Inc. 以獲得 Staccato® 阿普唑仑，並與 Alexza
More news about: 李氏大藥廠
Dec 09, 2025, 17:39 ET Antero Midstream Announces Pricing of Upsized $600 Million Offering of Senior Notes
Special Mandatory Redemption Outside Date, the HG Purchase Agreement is terminated according to its terms without the closing of the HG Acquisition or (iii) Antero Midstream Partners determines based on its reasonable judgment that the HG Acquisition will not close prior to the Special Mandatory Redemption
More news about: Antero Midstream Corporation
Dec 09, 2025, 17:31 ET Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
and NeuroSense is advancing it through regulatory pathways while preparing for a pivotal Phase III trial. Following favorable feedback from the FDA, the company plans to initiate a multinational Phase III study in the second half of 2025.CERES Brain Therapeutics' CBT101 is a creatine prodrug
More news about: DelveInsight Business Research, LLP
Dec 09, 2025, 16:15 ET UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF CALIFORNIA
converting ClVIF to PX at commercial scale; (ii) the fouling issues were causing substantial delays during the FEL 2 phase of the Origin 2 project; (iii) the Individual Defendants had been planning internally to scale down production of PX at Origin 2 or to shift focus toward another product; (iv) the
More news about: Origin Materials, Inc.
Dec 09, 2025, 16:05 ET CRACKER BARREL REPORTS FIRST QUARTER FISCAL 2026 RESULTS AND UPDATES FISCAL 2026 OUTLOOK
2025, store closing costs, (ii) expenses related to the proxy contest in connection with the Company's 2024 and 2025 annual meeting of shareholders, (iii) expenses associated with the Company's strategic transformation initiative, (iv) a corporate restructuring charge that includes consulting fees related
More news about: Cracker Barrel Old Country Store, Inc.
Dec 09, 2025, 16:05 ET Perimeter Medical Imaging AI Closes C$3.6 Million Non-Brokered Private Placement
material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include,
More news about: Perimeter Medical Imaging AI Inc.
Dec 09, 2025, 16:05 ET American Outdoor Brands, Inc. Reports Second Quarter Fiscal 2026 Financial Results
and the reader to review, as applicable, both (1) GAAP measures that include (i) amortization of acquired intangible assets, (ii) stock compensation, (iii) non-recurring inventory reserve adjustment, (iv) emerging growth status transition costs, (v) technology implementation, (vi) income tax adjustments,
More news about: American Outdoor Brands, Inc.
Dec 09, 2025, 16:00 ET Ziegler Prices $175,000,000 Financing for Beacon Hill at Eastgate (MI)
be used to (i) finance a planned expansion at the Community (the "Expansion Project"), (ii) pay capitalized interest on the Bonds through July 2028, (iii) make a deposit to the debt service reserve fund, and (iv) pay certain costs of issuing the Bonds.Like prior expansions dating back to 2010 at
More news about: Ziegler
Dec 09, 2025, 15:07 ET Schwarzman Animal Medical Center Completes a Four-Year, 83,000 Square-Foot, and $125 Million Transformation
Unit, Medical-Surgical Unit, Avian & Exotic Pet Medicine service, and Education and Conference Center.In December 2025, AMC completed Phase III with a new Emergency Room alongside clinical spaces for Cardiology, Radiology, Ophthalmology, Neurology, and Internal Medical services.Throughout
More news about: Schwarzman Animal Medical Center
Dec 09, 2025, 11:00 ET Balance Point Completes Closings for Its 8th and 9th Funds, Raising Over $880 Million
2025. Assets under management is calculated as the sum of (i) the total asset value determined in accordance with GAAP, (ii) unfunded commitments, and (iii) undrawn committed or assumed SBA leverage, where applicable.Media Contact: Adam H. SauerteigOffice: 203-652-8555
More news about: Balance Point Capital
Dec 09, 2025, 10:00 ET Institute Study Finds Solution to Annuity Adoption Gap: How Integrating Lifetime Income Options to Retirement Plans Transforms Retiree Behavior
all of TIAA's annuity products.iii. As of September 30, 2025, assets under
More news about: TIAA Institute
Dec 09, 2025, 10:00 ET Principal® Foundation Launches Award Program to Honor Principal® Financial Network Professionals Driving Community Impact
Manuel Carril IIISales Creek, Tennessee
More news about: Principal Foundation
Dec 09, 2025, 09:00 ET Lost Money on Skye Bioscience, Inc.(SKYE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
effective than defendants had led investors to believe; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.WHAT'S NEXT? If you suffered a loss
More news about: Levi & Korsinsky, LLP
Dec 09, 2025, 09:00 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Firefly Aerospace Inc.(FLY) Shareholders
for its Spacecraft Solutions offerings; (ii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (iii) the foregoing, once revealed, would likely have a material negative impact on the Company; and (iv) as a result, the offering documents and defendants'
More news about: Levi & Korsinsky, LLP
Dec 09, 2025, 09:00 ET Investors who lost money on DeFi Technologies(DEFT) should contact Levi & Korsinsky about pending Class Action - DEFT
treasury companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly,
More news about: Levi & Korsinsky, LLP
Dec 09, 2025, 09:00 ET Shareholders that lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class Action - DXCM
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: Levi & Korsinsky, LLP
Dec 09, 2025, 09:00 ET ANDREWS & SPRINGER LLC ANNOUNCES PROPOSED SETTLEMENT OF STOCKHOLDER CLASS ACTION INVOLVING PLAYTIKA HOLDING CORP.
should be finally appointed as Class Representative for the Class and Plaintiffs' Counsel should be finally appointed as Class Counsel for the Class; (iii) determine whether the proposed Settlement should be approved as fair, reasonable, and adequate to Plaintiffs and the other members of the Class; (iv)
More news about: Andrews & Springer LLC
Dec 09, 2025, 08:39 ET Bora Pharmaceuticals and Corealis Pharma Forge Strategic Alliance to Deliver Seamless, End-to-End Oral Solid Dose Development
David Leroux-Petersen, CEO of Corealis Pharma. "The alliance with Bora provides our early-stage partners with a clear, fast, seamless, simple path to phase III manufacturing and commercial launch."Bora Pharmaceuticals is a premier international contract development and manufacturing organization
More news about: Bora Pharmaceuticals
Dec 09, 2025, 08:30 ET Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing,
More news about: Citius Oncology, Inc.
Dec 09, 2025, 08:00 ET Planet Green Holdings Corp. Receives NYSE Deficiency Notification Regarding Shareholders' Equity
"Company") received a notice from the New York Stock Exchange ("NYSE") that it is below the continued listing criteria under Sections 1003(a)(i), (ii), and (iii) o of the NYSE's listing standards set forth in Part 10 of the NYSE American Company Guide ("Company Guide"), because the Company reported stockholders'
More news about: Planet Green Holdings Corp.